Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 19/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 18/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18379794 | 0.87 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL13735514 | 0.81 | HDAC2 (0.74) | HDAC2HDAC1HDAC3 | |
| SCHEMBL13735376 | 0.76 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL18379855 | 0.75 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL13737029 | 0.72 | HDAC1 (0.73) | HDAC2HDAC1HDAC3 | |
| SCHEMBL13735195 | 0.72 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL18079542 | 0.71 | HDAC2 (0.55) | HDAC2HDAC1HDAC3 | |
| SCHEMBL20367007 | 0.70 | HDAC2 (0.65) | HDAC2HDAC1HDAC3 | |
| SCHEMBL18379960 | 0.70 | HDAC2 (0.68) | HDAC2HDAC1HDAC3 | |
| SCHEMBL18379621 | 0.69 | HDAC1 (0.69) | HDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210277007-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-09-09 | — | — | US | disclosed |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | disclosed |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
| WO-2017007756-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | RODIN THERAPEUTICS, INC (US) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | HDAC2 1/4885HDAC1 2/4885HDAC3 5/4885 |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | HDAC2 1/4885HDAC1 2/4885HDAC3 5/4885 |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | HDAC2 1/4885HDAC1 2/4885HDAC3 5/4885 |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | HDAC2 1/4885HDAC1 2/4885HDAC3 5/4885 |
| US-20210277007-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | HDAC2 1/4885HDAC1 2/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.